ReviewInternational health2016
Antimalarial mass drug administration: ethical considerations.
Review in International health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Reactive Case Detection and Treatment and Reactive Drug Administration for Reducing Malaria Transmission: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2024Pooled it
- Mass drug administration for neglected tropical disease control and elimination: a systematic review of ethical reasons.BMJ global health · 2024Pooled it
- Transition of radical, preventive and presumptive treatment regimens for malaria in China: a systematic review.Malaria journal · 2021Pooled it
- Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review.Malaria journal · 2016Pooled it
- Trial
- Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.BMC medicine · 2018Trial
- Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial.The Lancet. Global health · 2018Trial
- Community perspectives on mass malaria vaccine and drug administration in the Chittagong Hill Tracts, Bangladesh: a qualitative study.Malaria journal · 2026Article
- Application Strategy and Research Progress of Large-Scale Population Drug Intervention in Malaria Control.Tropical medicine and infectious disease · 2026Review
- Wonder drugs and where to use them: a forecast of ivermectin's impact on malaria in Africa.Infectious Disease Modelling · 2025Article
- Article
- Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts.Malaria journal · 2024Review
- Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery-An Update.Advances in medicine · 2023Review
- Empowering local research ethics review of antibacterial mass administration research.Infectious diseases of poverty · 2022Review
- Ethical challenges in mass drug administration for reducing childhood mortality: a qualitative study.Infectious diseases of poverty · 2022Article
- Article
- From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia.Malaria journal · 2021Article
- Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.Malaria journal · 2021Article
- Understanding adherence to reactive treatment of asymptomatic malaria infections in The Gambia.Scientific reports · 2021Article
- Genetic Variation ofFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Falciparum malaria is a major cause of death and illness in tropical countries, particularly in childhood. In endemic countries, a significant proportion of the community is infected with malaria asymptomatically. One promising way to eliminate malaria is to give the entire population malaria treatment. This is called mass drug administration (MDA) and it raises a number of ethical issues, as possible long-term benefits are uncertain. The effectiveness of MDA is critically dependent on level of participation, so the promised benefits to the community can be annulled by non-participation of a small number of individuals. These potential benefits range a wide spectrum, from the permanent elimination of malaria (success) to a transient reduction in the prevalence of infection and the incidence of illness (failure). The drawbacks of MDA are: inconvenience, potential toxicity, loss of confidence in the elimination campaign, possible drug resistance (though highly unlikely), and the potential for a rebound of malaria illness (if immunity is lost and malaria is reintroduced later). Other ethical issues are related to balancing individual and public health interests, and potentially limiting individual autonomy by making MDA compulsory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.